Chirag Shah, MD, of the Cleveland Clinic, discusses the impact of DCISionRT testing on radiation therapy recommendations for patients with ductal carcinoma in situ following lumpectomy. His study found that despite using traditional favorable-risk criteria, radiation recommendations were changed in more than 40% of patients (Abstract PS6-17).
Nadia Harbeck, MD, of the University of Munich, discusses the first outcome data from the phase III ADAPT HR+/HER– trial, which combined both static and dynamic biomarkers to...
Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dos...
Joyce V. Lee, PhD, of the University of California, San Francisco, discusses data that suggest the MYC oncogene may indicate whether a patient with triple-negative b...
In her recent study, Debra A. Pratt, MD, of the Cleveland Clinic, showed that when breast cancer treatment using any of three modalities takes longer than 38 weeks, it is ass...
Sara A. Hurvitz, MD, of the David Geffen School of Medicine at UCLA, discusses phase III data from the ASCENT study of the antibody-drug conjugate sacituzumab govitecan vs ch...